Tags

Type your tag names separated by a space and hit enter

Omega-3 Fatty Acids and Age-Related Macular Degeneration.

Abstract

Against a background of considerable epidemiological and other evidence implicating omega-3 fatty acids in the prevention of age-related macular degeneration (AMD), the negative results of the Age-Related Disease Study 2 (AREDS2) were unexpected. The possibility that the design, setting, intake or subjects of AREDS2 may not have permitted the prophylactic potential of omega-3 to be adequately demonstrated is considered. Epidemiological studies had indicated potential preventative effects of omega-3, and an earlier randomised prospective study (NAT2) showed that patients who achieved high red blood cell membrane EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) levels were significantly protected against AMD compared with those with permanently low EPA/DHA levels. Various methodological differences between these studies are considered. NAT2 included a true placebo group, whereas control subjects in AREDS2 received a nutritional formula already found to be effective in AREDS1, but no placebo for DHA/EPA supplementation. Differences in the handling of non-compliant subjects and the formulation of the test formulations are considered. Given these considerations, and other lines of evidence from laboratory and clinical studies, closing the chapter on omega-3 in AMD prevention may be premature.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK.

    , , , , ,

    Source

    Ophthalmic research 55:2 2015 pg 62-9

    MeSH

    Diet
    Dietary Supplements
    Epidemiologic Studies
    Fatty Acids, Omega-3
    Fish Oils
    Humans
    Macular Degeneration

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    26610051

    Citation

    Souied, Eric H., et al. "Omega-3 Fatty Acids and Age-Related Macular Degeneration." Ophthalmic Research, vol. 55, no. 2, 2015, pp. 62-9.
    Souied EH, Aslam T, Garcia-Layana A, et al. Omega-3 Fatty Acids and Age-Related Macular Degeneration. Ophthalmic Res. 2015;55(2):62-9.
    Souied, E. H., Aslam, T., Garcia-Layana, A., Holz, F. G., Leys, A., Silva, R., & Delcourt, C. (2015). Omega-3 Fatty Acids and Age-Related Macular Degeneration. Ophthalmic Research, 55(2), pp. 62-9. doi:10.1159/000441359.
    Souied EH, et al. Omega-3 Fatty Acids and Age-Related Macular Degeneration. Ophthalmic Res. 2015;55(2):62-9. PubMed PMID: 26610051.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Omega-3 Fatty Acids and Age-Related Macular Degeneration. AU - Souied,Eric H, AU - Aslam,Tariq, AU - Garcia-Layana,Alfredo, AU - Holz,Frank G, AU - Leys,Anita, AU - Silva,Rufino, AU - Delcourt,Cécile, Y1 - 2015/11/27/ PY - 2015/09/15/received PY - 2015/09/23/accepted PY - 2015/11/27/entrez PY - 2015/11/27/pubmed PY - 2016/7/14/medline SP - 62 EP - 9 JF - Ophthalmic research JO - Ophthalmic Res. VL - 55 IS - 2 N2 - Against a background of considerable epidemiological and other evidence implicating omega-3 fatty acids in the prevention of age-related macular degeneration (AMD), the negative results of the Age-Related Disease Study 2 (AREDS2) were unexpected. The possibility that the design, setting, intake or subjects of AREDS2 may not have permitted the prophylactic potential of omega-3 to be adequately demonstrated is considered. Epidemiological studies had indicated potential preventative effects of omega-3, and an earlier randomised prospective study (NAT2) showed that patients who achieved high red blood cell membrane EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) levels were significantly protected against AMD compared with those with permanently low EPA/DHA levels. Various methodological differences between these studies are considered. NAT2 included a true placebo group, whereas control subjects in AREDS2 received a nutritional formula already found to be effective in AREDS1, but no placebo for DHA/EPA supplementation. Differences in the handling of non-compliant subjects and the formulation of the test formulations are considered. Given these considerations, and other lines of evidence from laboratory and clinical studies, closing the chapter on omega-3 in AMD prevention may be premature. SN - 1423-0259 UR - https://www.unboundmedicine.com/medline/citation/26610051/full_citation L2 - https://www.karger.com?DOI=10.1159/000441359 DB - PRIME DP - Unbound Medicine ER -